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Most research in gout has concentrated on the
proinflammatory mechanisms to explain the
inflammation that is generated when leucocytes are in
contact with monosodium urate crystals. However, the
episodic nature of gout and the absence of
inflammation even when crystals are present suggest
that there are natural counter-regulatory mechanisms
to limit the inflammatory response. Gagné and
colleagues showed that myeloid inhibitory C-type
lectin, a C-type lectin inhibitory receptor expressed on
neutrophils, modulates monosodium urate-induced
neutrophil responses in vitro.In their studies, Gagné and colleagues showed thatNeutrophil recruitment and activation play a key role in
the acute inflammatory response to monosodium urate
(MSU) crystals. In acute gout, our current treatments
such as nonsteroidal anti-inflammatory drugs, colchicine
or corticosteroids all act on different steps of neutrophil
activation. These drugs form part of the first treatment
objective in gout – to relieve the painful symptoms of
the acute attack – but do not address the second object-
ive, which is to treat the underlying metabolic disorder
hyperuricemia. Can neutrophil activation be manipu-
lated or regulated? Are there signals that can be modu-
lated and can this be of clinical relevance?
The article by Gagné and colleagues provides evidence
for an inhibitory pathway of neutrophil activation that
acts through a recently described C-type lectin receptor
called the myeloid inhibitory C-type lectin (MICL) [1].
This membrane receptor, also known as CLEC12A, in-
hibits neutrophil activation when it is engaged. C-type
lectin receptors form a large family of proteins that have
a common type of carbohydrate-binding domain that
mediate cell adhesion and ligand binding in a calcium-
dependent manner. Members of the C-type lectinCorrespondence: AlexanderKai-Lik.So@chuv.ch
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tion, with well-known examples including Dectin-1
(CLE7A), DC-sign (CD209 or CLEC4L) and natural
killer cell receptors (Ly49 or KLRA1). The MICL protein
is encoded on chromosome 12p13, closely linked to the
natural killer gene complex. MICL contains a cytoplas-
mic immunoreceptor tyrosine-based inhibitory motif
and is expressed mainly on neutrophils and monocytes.
Previous work has shown that the receptor could inhibit
cellular activation [2]. The ligands that lead to MICL ac-
tivation are currently unknown, as there is only a small
body of data to show that the receptor interacts with li-
gands expressed in the bone marrow, thymus and kidney
[3].
MSU crystals as well as a MICL-specific antibody
downmodulated MICL expression on neutrophils. Redu-
cing the expression of MICL by transfecting small inter-
fering RNA or by antibody modulation of the receptor
led to enhanced production of IL-8 when MSU was
added to neutrophils, but no changes in IL-1β secretion
were observed. The mechanisms of MICL signaling
probably involve tyrosine phosphorylation as well as cal-
cium flux, differing from previous results that showed
MICL associated with the phosphatases SHP-1 and
SHP-2 [2]. Finally, the addition of colchicine to neutro-
phils abrogated the negative effect of MSU on MICL
expression.
These results showed that reduced MICL expression is
associated with augmented inflammatory responses from
neutrophils, and a higher level of neutrophil MICL ex-
pression is associated with a reduced IL-8 production
in vitro. As IL-8 is a major neutrophil chemoattractant,
this can have important effects on neutrophil recruit-
ment to an inflammatory site in gout. By extrapolation,
if MICL expression or signaling could be enhanced or
maintained during inflammation, the inhibitory signal
may be reinforced and thereby downregulate inflamma-
tion. The effect of colchicine in this system is to elevate
the expression of MICL, thereby increasing the
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A number of caveats need to be mentioned in the in-
terpretation of these results. The data presented were
based on in vitro models of inflammation using MSU,
and we need to see how this works in vivo before com-
ing to any conclusions, as we have had examples where
the in vivo results did not recapitulate the in vitro find-
ings. They convincingly showed that reducing MICL ex-
pression on the surface of neutrophils enhanced the
proinflammatory signature, but they did not show the
converse – that enhanced MICL signaling can further
downmodulate inflammation. Furthermore, the ligands
that bind and activate MICL are unknown, so we have
no idea what is the signal or how to reinforce or ma-
nipulate this signaling system. The results presented
show that MSU had dual effects on neutrophils – the
first is to downregulate MICL expression, and the sec-
ond is to activate IL-8 production. How are these two
mechanisms linked? If MSU acts mainly on the cell
membrane internalization of MICL, what is the trigger
for the IL-8 secretion? Notwithstanding these uncertain-
ties, the finding that MICL modulates neutrophil activa-
tion in gout suggests that there are a number of
counter-regulatory mechanisms in operation during an
inflammatory process. Identifying these mechanisms
may help us to understand the nature of gout as well as
open up new therapeutic perspectives.
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